On August 3, 2016 NantHealth, Inc. (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, reported that Sanford Health, one of the largest health systems in the nation, has entered into a commercial license agreement for the use of its eviti, the evidence-based treatment intelligence and web-based oncology decision support platform, which was recently named #1 Clinical Decision Support solution for 2016 by Black Book Market Research (Press release, NantHealth, AUG 3, 2016, View Source [SID:1234514219]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under terms of the agreement, Sanford Health’s network of oncologists will have access to NantHealth’s eviti Connect decision support solution, providing them with evidence-based regimens, condition-specific clinical trial options and the potential for more efficient preauthorization and expedited reimbursement. Further, the eviti service holds the promise of delivering OMICS data for bio-specific therapy. Sanford Health, based in the Dakotas, joins over 75 percent of U.S. oncology practices who have used the eviti platform to make better clinical decisions earlier in the treatment process.
eviti Connect will be deployed to streamline system-wide processes for the prescribing of high-quality, cost-effective treatments while improving the flow of information between Sanford Health and its providers. All of the participants in the cancer care process benefit from eviti’s collaborative, real-time approach to improving care and lowering risks and costs.
In order for oncologists to serve as many cancer patients as possible, select treatment plans with the best possible outcome, and with the most responsible economic profile, the technology solution must have the rapid-learning and data compilation capabilities of true super-computing. eviti’s clinical decision support is easy to use while computing massive amounts of complex data to quickly present appropriate treatment options, including the latest peer-reviewed and proprietary immunotherapy clinical trials. eviti applications go beyond the capabilities of most traditional electronic medical records systems to present treatment options personalized for each patient’s need.
"Sanford Health Plan is committed to offering oncologists in our networks the support they need to provide the best, most advanced patient care possible," said Kirk Zimmer, Executive Vice President, Sanford Health Plan. "eviti gives physicians real-time access to the widest range of evidenced-based treatment options available, and further, to ensure that the care they provide meets the clinical requirements for reimbursement. This comprehensive approach stands to improve clinical outcomes, while reducing claims denials and potentially costs."
The eviti platform provides physicians real-time access to its comprehensive, unbiased Evidence-Based Medical Library, which encompasses over 2,700 of the most appropriate, evidence-based treatment regimens covering all cancers and cancer subtypes and all modalities. Each regimen incorporates level of evidence, expected clinical outcomes, treatment costs, toxicities and any supporting literature. This evidence-based medical library is meticulously compiled from peer-reviewed literature, oncology associations, and government agencies. The library is maintained by a full-time team of oncologists and oncology nurses, clinical informatics professionals, and an advisory board of nationally recognized oncology experts.
"We are pleased to enter into this partnership with Sanford Health and look forward to working with the organization to enable their oncologists to more quickly see and evaluate the spectrum of appropriate treatment options in order to make even better, and more informed treatment decisions," said Patrick Soon-Shiong, M.D., CEO of NantHealth. "Today, independent studies show that nearly 32 percent of oncology treatment plans deviate from evidence-based standards without medical justification. While this is understandable given the rapidly growing number of treatment options available to patients and their caregivers, we must do better. Our goal is to provide a single, reliable source of the most current information available to physicians, enabling them to provide the right care at the right time—and to immediately know whether that care will be covered."